The probiotic Escherichia coli Nissle 1917 reduces pathogen invasion and modulates cytokine expression in Caco-2 cells infected with crohn's disease-associated E. coli LF82

Applied and Environmental Microbiology

Volumn 77, Issue 7, 2011, Pages 2541-2544

  Huebner, Claudia ^a,c   Ding, Yaoyao ^a,c   Petermann, Ivonne ^a,c,d   Knapp, Christoph ^b   Ferguson, Lynnette R ^a,c  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Nutrigenomics New Zealand   (New Zealand)

^d Sch Life Sci Technol Victoria U   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CACO-2 CELLS; CROHN'S DISEASE; CYTOKINE EXPRESSION; E. COLI; NISSLE 1917; PROBIOTICS; REFERENCE STRAINS;

ESCHERICHIA COLI;

CYTOKINE; PROBIOTIC AGENT;

COLIFORM BACTERIUM; DIGESTIVE SYSTEM; INVASIVE SPECIES; PATHOGEN; PATHOGENICITY; PROBIOTICS;

ANTIBIOSIS; ARTICLE; CELL STRAIN CACO 2; CROHN DISEASE; EPITHELIUM CELL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PATHOGENICITY; SECRETION;

ANTIBIOSIS; CACO-2 CELLS; CROHN DISEASE; CYTOKINES; EPITHELIAL CELLS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; PROBIOTICS;

ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917;

EID: 79953292158     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01601-10     Document Type: Article

References (21)

1. Barnich, N., et al. 2007. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J. Clin. Invest. 117:1566-1574.
2. Baumgart, M., et al. 2007. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 1:403-418.
3. Boudeau, J., N. Barnich, and A. Darfeuille-Michaud. 2001. Type 1 pilimediated adherence of Escherichia coli strain LF82 isolated from Crohn's disease is involved in bacterial invasion of intestinal epithelial cells. Mol. Microbiol. 39:1272-1284.
4. Boudeau, J., A.-L. Glasser, S. Julien, J.-F. Colombel, and A. Darfeuille-Michaud. 2003. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherentinvasive E. coli strains isolated from patients with Crohn's disease. Aliment. Pharmacol. Ther. 18:45-56.
5. Darfeuille-Michaud, A., et al. 2004. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127:412-421.
6. Darfeuille-Michaud, A., et al. 1998. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology, 115:1405-1413.
7. Falkow, S., P. Small, R. Isberg, S. Hayes, and D. Corwin. 1987. A molecular strategy for the study of bacterial invasion. Rev. Infect. Dis. 9(Suppl. 5): S450-S455.
8. Frank, D., et al. 2007. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 104:13780-13785.
9. Fujimura, K. E., N. A. Slusher, M. D. Cabana, and S. V. Lynch. 2010. Role of the gut microbiota in defining human health. Expert Rev. Anti Infect. Ther. 8:435-454.
10. Hidalgo, I. J., T. J. Raub, and R. T. Borchardt. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749.
11. Huebner, C., I. Petermann, W. J. Lam, A. N. Shelling, and L. R. Ferguson. 2010. Characterization of single-nucleotide polymorphisms relevant to inflammatory bowel disease in commonly used gastrointestinal cell lines. Inflamm. Bowel Dis. 16:282-295.
12. Kamada, N., et al. 2008. Nonpathogenic Escherichia coli strain Nissle 1917 inhibits signal transduction in intestinal epithelial cells. Infect. Immun. 76: 214-220.
13. Kruis, W., et al. 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617-1623.
14. Kruis, W., et al. 1997. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11:853-858.
15. Maaser, C., L. Eckmann, G. Paesold, H. S. Kim, and M. F. Kagnoff. 2002. Ubiquitous production of macrophage migration inhibitory factor by human gastric and intestinal epithelium. Gastroenterology 122:667-680.
16. Martinez-Medina, M., et al. 2009. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherentinvasive E. coli (AIEC) in Crohn's disease. Inflamm. Bowel Dis. 15:872-882.
17. Rembacken, B. J., A. M. Snelling, P. M. Hawkey, D. M. Chalmers, and A. T. Axon. 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354:635-639.
18. Riedel, C. U., et al. 2006. Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-κB activation. World J. Gastroenterol. 12: 3729-3735.
19. Sokol, H., et al. 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U. S. A. 105:16731-16736.
20. Turnbaugh, P. J., et al. 2009. A core gut microbiome in obese and lean twins. Nature 457:480-484.
21. Xavier, R., and D. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427-434.